DNA with chromosomes in the background. Ella Maru Studio
Cancer treatment is being revolutionized by drugs that prevent tumour cells from repairing their DNA.
Drugs targeting cancer cell DNA repair have been heralded as a game-changer for multiple cancers compared to traditional therapies like chemotherapy. This promises more precisely targeted treatments, better tolerance, and improved survival for patients. They exploit the imperfect DNA repair machinery found in many cancer cells, which makes them heavily rely on specific remaining repair pathways to survive and reproduce. Blocking these pathways leads to DNA damage building up and ultimately cancer cell death, while the healthy cells that retain alternative DDR pathways survive.
UK based Novartis are collaborating with Artios Pharma in new research to target and validate next generation DNA Damage Response (DDR) targets to enhance Novartis’s Radioligand Therapies (RLT)
“This collaboration expands the reach of our discovery platform, leveraging our DDR expertise and target knowledge to enhance the potential of radioligand therapies,” states Artios CEO Niall Martin.
Oncology PRO DNA Replication Stress and Cancer
European Pharmaceutical Manufacturer Artios Pharma Collaboration with Novartis
Labiotech.eu Artios-Novartis Pact Pushes Limits of DNA Repair in Cancer